New study tracks PKU drug palynziq in pregnancy: what are the risks?
NCT ID NCT05579548
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows 50 pregnant women with phenylketonuria (PKU) who have taken the drug Palynziq (pegvaliase) around the time of pregnancy or while breastfeeding. Researchers will track pregnancy outcomes and infant health, including birth defects and development. The goal is to gather real-world safety data, not to test a new treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Pegvaliase (Palynziq)
- What this could lead to
- If successful, this study could provide crucial safety information for pregnant women with PKU who need Palynziq, helping doctors and patients make informed decisions.
- What could go wrong
- This is an observational study, not a controlled trial, so it cannot prove cause and effect. The small size (50 participants) limits how much we can learn, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PHENYLKETONURIA, MATERNAL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Metabolics and Genetics in Calgary (MAGIC)
RECRUITINGCalgary, T2E 7Z4, Canada
-
Ospedale San Paolo
RECRUITINGMilan, 20142, Italy
-
Syneos Health
RECRUITINGWilmington, North Carolina, 28403, United States
Contact Email: •••••@•••••
-
Universitaetsklinikum Hamburg Eppendorf
RECRUITINGHamburg, 20246, Germany